Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

Regeneron Pharmaceuticals' Libtayo won approval to treat certain patients with cutaneous squamous cell carcinoma, a type of skin cancer, from the Food and Drug Administration. The pharmaceutical ...

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed ...

Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 2% Wednesday following the FDA’s approval of its drug Libtayo for the adjuvant treatment of adults with cutaneous squamous cell ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September ...

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...